The results of one- and two-dimensional echocardiography in 151 patients (139 males, 12 females;median age 37 years) who were seropositive for human immunodeficiency virus type 1 were analyzed in addition to clinical and laboratory data. Echocardiographie abnormalities probably related to human immunodeficiency virus type 1 were identified in 31 patients (20%): pericardial effusions (n = 29) and left ventricular dilation (n = 4). Compared to patients with normal échocardiographie findings, patients with échocardiographie abnormalities had lower mean T4 lymphocyte counts (142 ± 148 vs. 280 ± 231/µl; p < 0.001), the proportion of hospitalized patients was higher (16/31 vs. 33/107; p < 0.05), and active concomitant diseases were more frequently found (22/31 vs. 39/107; p < 0.001). T4 lymphocyte counts < 100/µl could be identified as a risk factor for the development of cardiac manifestations. There was no difference in the mortality of patients with and without échocardiographie abnormalities.

Keywords:
Human immunodeficiency virus infection, Heart diseases, Echocardiography
This content is only available via PDF.
1991
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.